Tag: Lonza

Lonza launches its new HPAPI suites in Switzerland

lonza
Lonza (Switzerland), a specialty CDMO, announced an expansion of its highly potent API (HPAPI) capacity for the specific support of antibody drug conjugate (ADC) payload manufacturing. This latest ...

Lonza initiated a pharmaceutical early-intermediates supply initiative

lonza building
The initiative leverages chemical production facilities at the company’s Visp (Switzerland) site to address increasing global early-intermediates supply security and quality concerns.

Lonza expands its Capsugel R&D offering

capsules
Capsule Delivery Solutions, part of Lonza Pharma & Biotech, is launching the Capsugel® Colorista™ product, a high-quality capsule based on an “all-colorants” formulation.

Lonza Bioscience launches a new bioresearch website

lonza
Lonza Bioscience, one of the leading suppliers to the the pharmaceutical, biotech and specialty ingredients markets, launches its new dedicated website.

Lonza announced a distribution agreement with Innosieve Diagnostics

lonza
Lonza Pharma & Biotech and Innosieve Diagnostics announced an exclusive distribution agreement for rapid bioburden testing technology.

Lonza became CAR-Treg cellular product manufacturer for TxCell

lonza building
TxCell and Lonza entered into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation.

Lonza will host a webinar focused on CRISPR technology

gene
Today, CRISPR/Cas9 has emerged as the genome editing method of choice in research and biotechnology. Compared to other gene editing technologies, it is simpler to re-engineer, easier to use, and can target multiple sites.

Lonza invests in expansion of its US facility

lonza
Lonza Pharma & Biotech announced the investment in a new phase of development at their Portsmouth (New Hampshire, USA) site. The expansion will include mid-scale mammalian capacity and the addition of new cell-therapy suites.

Synpromics entered a biopharmaceutical partnership with Lonza

gene editing
Synpromics Ltd, the leader in gene control, announced a partnership with Lonza Pharma & Biotech to further develop its inducible promoter system and improve manufacturing of biopharmaceuticals.

Lonza launched its dedicated cell-and-gene-therapy facility in USA

lonza building
Lonza opened the world’s largest dedicated cell-and-gene-therapy facility, which was built in anticipation of the rising demand from developers of cell and gene therapies.

Lonza to Host New Webinar: “Integrating Devices into Quality Systems”

On 24 April 2018, Lonza is hosting a free 60-minute webinar on the best practices for connecting and integrating devices and systems in QC and production, which I thought would be of interest to you and your readers.

Lonza boosts manufacturing capabilities in USA

lonza
Lonza, a Swiss chemicals and biotechnology, company announced the expansion of its late-stage clinical and commercial encapsulation capabilities for solid oral and inhaled dosage forms in USA.

Lonza and Denali Therapeutics teamed up to develop biologic medicines

lonza building
Lonza Pharma & Biotech and Denali Therapeutics announced an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases

New software from Lonza will provide regulatory guidance for scientists

good laboratory practice
Lonza’s MODA-EM Version 3.3 software enables microbiology Quality Control laboratories to comply with new regulatory guidelines

Lonza launches new R&D Collaborative Innovation Center in Israel

lonza
Lonza announced the establishment of the Lonza Collaborative Innovation Center (CIC) in the new Life Science Park in the outskirts of Haifa, Israel

Lonza widens its drug manufacturing capabilities

lonza building
Swiss pharmaceutical company, Lonza, announced that its Pharma & Biotech segment is expanding its footprint for Parenteral Dosage Form development with a further build-out of its Drug Product Services